In 2020, the combination therapy of nivolumab and ipilimumab (an CTLA-4 inhibitor) was approved for the treatment of patients with metastatic NSCLC without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic aberrations (45, 46). This evidence concerns the gene EGFR and non-small cell lung carcinoma.